Group 1 - The core point of the article is that 康龙化成 (Kanglong Chemical) has seen a significant stock price increase of over 5%, reaching a rise of 7.81% to HKD 23.18, with a trading volume of HKD 299 million [1] - The company announced that 信中康成 (Xinchun Kangcheng) has completed its share reduction plan, resulting in a total reduction of 26.67 million shares [1] - 康龙化成 reported its interim results for the six months ending June 30, 2025, with revenue of RMB 6.441 billion, a year-on-year increase of 14.9%, and a gross profit of RMB 2.172 billion, reflecting a 17.5% year-on-year growth [1]

Core Viewpoint - 康龙化成's stock price increased by over 5%, reaching a rise of 7.81% to HKD 23.18, with a trading volume of HKD 299 million [1] Group 1: Shareholding Changes - 康龙化成 received a notification from 信中康成 and its associated party 深圳市信中龙成投资合伙企业 regarding the completion of a share reduction plan, with a total of 26.67 million shares being sold [1] Group 2: Financial Performance - 康龙化成 reported a revenue of RMB 6.441 billion for the six months ending June 30, 2025, representing a year-on-year growth of 14.9% [1] - The gross profit for the same period was RMB 2.172 billion, showing a year-on-year increase of 17.5% [1] - The basic earnings per share were RMB 0.3984 [1]

Core Viewpoint - 康龙化成's stock has shown a positive trend with a year-to-date increase of 18.78%, reflecting strong market interest and performance in the biopharmaceutical sector [1][2]. Financial Performance - As of June 30, 康龙化成 reported a revenue of 64.41 billion yuan for the first half of 2025, representing a year-on-year growth of 14.93% [2]. - The company's net profit attributable to shareholders was 7.01 billion yuan, which is a decrease of 37.00% compared to the previous period [2]. Stock Market Activity - On September 5, 康龙化成's stock price rose by 2.16%, reaching 30.29 yuan per share, with a trading volume of 5.46 billion yuan and a turnover rate of 1.29% [1]. - The total market capitalization of 康龙化成 is 538.62 billion yuan [1]. - The stock has experienced a 0.10% increase over the last five trading days, a 6.65% increase over the last 20 days, and a 22.93% increase over the last 60 days [1]. Shareholder Information - As of June 30, 康龙化成 had 87,900 shareholders, an increase of 10.12% from the previous period [2]. - The top ten circulating shareholders include 中欧医疗健康混合A, which holds 63.40 million shares, and 香港中央结算有限公司, which increased its holdings by 14.86 million shares [3]. Business Overview - 康龙化成 specializes in drug research, development, and production services, with its main revenue sources being laboratory services (60.43%), CMC services (21.58%), clinical research services (14.58%), and other services [1]. - The company operates within the medical and biopharmaceutical industry, focusing on medical research outsourcing [1].

Company News - Sun Hung Kai Properties (00016.HK) reported a revenue of HKD 79.721 billion for the fiscal year 2025, an increase of 11.5% year-on-year; net profit reached HKD 19.277 billion, up 1.2% year-on-year [2] - Sincere Watch International (00732.HK) recorded a net operating revenue of approximately HKD 11.011 billion for the first eight months, a decrease of 5.5% year-on-year; in August, the net operating revenue was about HKD 1.445 billion, down 6.5% year-on-year [2] Financial Activities - China Construction Bank (00939.HK) announced that CCB Financial Leasing plans to increase its capital by HKD 3 billion to CCB Shipping and Aviation [3] Pharmaceutical Developments - Heng Rui Medicine (01276.HK) received approval to conduct clinical trials for RSS0393 ointment, which can alleviate tissue damage and inflammation related to atopic dermatitis [4] - Heng Rui Medicine (01276.HK) also received approval for clinical trials of HRS-4729 injection, a tri-agonist for GLP-1R/GIPR/GCGR [4] Real Estate Sales Performance - China Overseas Land & Investment (00688.HK) reported a contracted sales amount of HKD 150.331 billion for the first eight months, a decline of 16.5% year-on-year; August contracted sales were HKD 18.33 billion, down 0.7% year-on-year [5] - Sunac China (01918.HK) recorded a contracted sales amount of approximately HKD 30.47 billion for the first eight months, a decrease of 13% year-on-year; August contracted sales were HKD 5.39 billion, down 26.7% year-on-year [5] - China Overseas Grand Oceans Group (00081.HK) reported a contracted sales amount of HKD 20.783 billion for the first eight months, a decline of 10.6% year-on-year; August contracted sales were HKD 2.133 billion, an increase of 6.1% year-on-year [5] - Gemdale Corporation (00535.HK) reported a total contracted sales of approximately HKD 7.588 billion for the first eight months, a decrease of 39% year-on-year; August contracted sales were HKD 608 million, down 52.9% year-on-year [5] - Hongyang Real Estate (01996.HK) reported a contracted sales amount of HKD 3.506 billion for the first eight months, a decrease of 42.2% year-on-year; August contracted sales were HKD 299 million, down 48.5% year-on-year [5] - Ronshine China Holdings (03301.HK) reported a contracted sales amount of approximately HKD 2.7 billion for the first eight months, a decline of 46.4% year-on-year; August contracted sales were about HKD 130 million, down 87.9% year-on-year [5] Share Buyback Activities - HSBC Holdings (00005.HK) repurchased 2.01 million shares at a cost of approximately HKD 200 million, with prices ranging from HKD 98.75 to HKD 100.3 [6] - Midea Group (00300.HK) repurchased 310,000 shares at a cost of approximately HKD 25.849 million, with prices ranging from HKD 83.3 to HKD 83.5 [6] - Hang Seng Bank (00011.HK) repurchased 210,000 shares at a cost of approximately HKD 23.799 million, with prices ranging from HKD 112.9 to HKD 113.7 [6] - MGM China Holdings (02282.HK) repurchased 1 million shares at a cost of approximately HKD 15.687 million, with prices ranging from HKD 15.58 to HKD 15.97 [6] Shareholding Changes - Kanglong Chemical (03759.HK) completed a share reduction plan, with a total of 26.6729 million shares reduced [6] - Sinopec Limited (00386.HK) canceled 67.624 million shares that had been repurchased [6]

Group 1 - The company 康龙化成 has received a notification letter from 信中康成 and its concerted party 深圳市信中龙成投资合伙企业 regarding the completion of a share reduction plan [1] - 信中康成 has cumulatively reduced its holdings by 26.6729 million shares [1]

Group 1 - The core point of the article is that 康龙化成 (Kanglong Chemical) has received a notification from 信中康成 (Xinchong Kangcheng) and its associated party, 深圳市信中龙成投资合伙企业 (Shenzhen Xinchong Longcheng Investment Partnership), regarding the completion of a share reduction plan [1] - 信中康成 has cumulatively reduced its holdings by 26.6729 million shares [1]

Group 1 - The core point of the article is that Kanglong Chemical (SZ 300759) announced the completion of a share reduction plan by its shareholder, Xincheng Kangcheng, who reduced approximately 26.67 million shares, accounting for 1.50% of the company's total shares [1] - As of the report date, Kanglong Chemical's market capitalization is 52.7 billion yuan [2] - For the year 2024, Kanglong Chemical's revenue composition is primarily from scientific research and technical services, which accounts for 99.95%, while other businesses contribute only 0.05% [1]

Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：3759） 香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 海外監管公告 本公告乃康龍化成（北京）新藥技術股份有限公司（「本公司」）根據香港聯合交易所 有限公司證券上市規則第13.10B條作出。 茲載列本公司於深圳證券交易所網站刊登公告如下，僅供參閱。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 中華人民共和國，北京 2025年9月4日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事萬璇女士及李家慶先生；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日在巨潮资讯网（www.c ...

本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）于 2025 年 5 月 16 日在巨潮资讯网（www.cninfo.com.cn）披露了《关于持股 5%以上股东减 持股份的预披露公告》（公告编号：2025-027）。公司持股 5%以上股东深圳市 信中康成投资合伙企业（有限合伙）（以下简称"信中康成"）计划自上述减持 公告披露之日起 15 个交易日（2025 年 6 月 10 日）后的 3 个月内以集中竞价交 易或大宗交易等深圳证券交易所认可的合法方式减持公司股份不超过 26,672,932 股（占公司总股本的 1.50%）。 公司于近日收到信中康成和其一致行动人深圳市信中龙成投资合伙企业（有 限合伙）（以下简称"信中龙成"）出具的告知函，获悉信中康成本次减持计划 已实施完毕，现将减持计划实施情况公告如下： 一、股东减持情况 证券代码：300759 证券简称：康龙化成 公告编号：2025-050 康龙化成（北京）新药技术股份有限公司 关于持股 5%以上股东减持计划实施完成的公告 公司持股 5%以上股东深圳市信中康成投资合伙企业（有限合 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | ...